Go to content
UR Home

Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation - a phase I study (MISOT-I).

URN to cite this document:
Popp, Felix C. ; Fillenberg, Barbara ; Eggenhofer, Elke ; Renner, Philipp ; Dillmann, Johannes ; Benseler, Volker ; Schnitzbauer, Andreas A. ; Hutchinson, James ; Deans, Robert ; Ladenheim, Deborah ; Graveen, Cheryl A ; Zeman, Florian ; Koller, Michael ; Hoogduijn, Martin J ; Geissler, Edward K. ; Schlitt, Hans J. ; Dahlke, Marc H.
License: Creative Commons Attribution 3.0
PDF - Published Version
Date of publication of this fulltext: 09 Sep 2011 09:46


BACKGROUND: Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to be reduced. In the current protocol, we propose to complement immunosuppressive pharmacotherapy ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons